Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1

Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1

Martha Sajatovic,1,2 Ruth Ross,3 Susan N Legacy,4 Christoph U Correll,5,6 John M Kane,5,6 Faith DiBiasi,7 Heather Fitzgerald,8 Matthew Byerly9 1Department of Psychiatry, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; 2Departments of Psychiatry and Neurology, Case Western Reserve...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sajatovic M, Ross R, Legacy SN, Correll CU, Kane JM, DiBiasi F, Fitzgerald H, Byerly M
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2018
Materias:
expert consensus
schizophrenia
schizoaffective disorder
bipolar disorder
long-acting injectable antipsychotics
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Acceso en línea:https://doaj.org/article/71a5f44f201f4553ac0ebe5e8a53449b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:71a5f44f201f4553ac0ebe5e8a53449b
record_format dspace
spelling oai:doaj.org-article:71a5f44f201f4553ac0ebe5e8a53449b2021-12-02T08:10:16ZIdentifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 11178-2021https://doaj.org/article/71a5f44f201f4553ac0ebe5e8a53449b2018-06-01T00:00:00Zhttps://www.dovepress.com/identifying-patients-and-clinical-scenarios-for-use-of-long-acting-inj-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Martha Sajatovic,1,2 Ruth Ross,3 Susan N Legacy,4 Christoph U Correll,5,6 John M Kane,5,6 Faith DiBiasi,7 Heather Fitzgerald,8 Matthew Byerly9 1Department of Psychiatry, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; 2Departments of Psychiatry and Neurology, Case Western Reserve University School of Medicine, Cleveland, OH, USA; 3Ross Editorial, Port Townsend, WA, USA; 4US Medical Affairs Neuroscience, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA; 5Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY, USA; 6Psychiatry, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Glen Oaks, NY, USA; 7Scientific Communications, Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA; 8Medical Affairs, Lundbeck LLC, Deerfield, IL, USA; 9Cell Biology and Neuroscience, Center for Mental Health Research and Recovery, Montana State University, Bozeman, MT, USA Objective: To assess expert consensus on barriers and facilitators for long-acting injectable antipsychotic (LAI) use and provide clinical recommendations on issues where clinical evidence is lacking, including identifying appropriate clinical situations for LAI use. Methods: A 50-question survey comprising 916 response options was distributed to 42 research experts and high prescribers with extensive LAI experience. Respondents rated options on relative appropriateness/importance using a 9-point scale. Consensus was determined using chi-square test of score distributions. Mean (standard deviation) ratings were calculated. Responses to 29 questions (577 options) relating to appropriate patients and clinical scenarios for LAI use are reported. Results: Recommendations aligned with research on risk factors for nonadherence and poor outcomes for patients with schizophrenia/schizoaffective or bipolar disorder. Findings suggested, contrary to general practice patterns, that LAI use may be appropriate earlier in the disease course and in younger patients. Results for bipolar disorder were similar to those for schizophrenia but with less consensus. Numerous facilitators of LAI prescribing were considered important, particularly that LAIs may reduce relapses and improve outcomes. Conclusion: Findings support wider use of LAIs in patients with schizophrenia/schizoaffective and bipolar disorders beyond the setting of poor adherence and earlier use in the disease course. Keywords: expert consensus, schizophrenia, schizoaffective disorder, bipolar disorder, long-acting injectable antipsychoticsSajatovic MRoss RLegacy SNCorrell CUKane JMDiBiasi FFitzgerald HByerly MDove Medical Pressarticleexpert consensusschizophreniaschizoaffective disorderbipolar disorderlong-acting injectable antipsychoticsNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 14, Pp 1463-1474 (2018)
institution DOAJ
collection DOAJ
language EN
topic expert consensus
schizophrenia
schizoaffective disorder
bipolar disorder
long-acting injectable antipsychotics
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle expert consensus
schizophrenia
schizoaffective disorder
bipolar disorder
long-acting injectable antipsychotics
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Sajatovic M
Ross R
Legacy SN
Correll CU
Kane JM
DiBiasi F
Fitzgerald H
Byerly M
Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1
description Martha Sajatovic,1,2 Ruth Ross,3 Susan N Legacy,4 Christoph U Correll,5,6 John M Kane,5,6 Faith DiBiasi,7 Heather Fitzgerald,8 Matthew Byerly9 1Department of Psychiatry, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; 2Departments of Psychiatry and Neurology, Case Western Reserve University School of Medicine, Cleveland, OH, USA; 3Ross Editorial, Port Townsend, WA, USA; 4US Medical Affairs Neuroscience, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA; 5Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY, USA; 6Psychiatry, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Glen Oaks, NY, USA; 7Scientific Communications, Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA; 8Medical Affairs, Lundbeck LLC, Deerfield, IL, USA; 9Cell Biology and Neuroscience, Center for Mental Health Research and Recovery, Montana State University, Bozeman, MT, USA Objective: To assess expert consensus on barriers and facilitators for long-acting injectable antipsychotic (LAI) use and provide clinical recommendations on issues where clinical evidence is lacking, including identifying appropriate clinical situations for LAI use. Methods: A 50-question survey comprising 916 response options was distributed to 42 research experts and high prescribers with extensive LAI experience. Respondents rated options on relative appropriateness/importance using a 9-point scale. Consensus was determined using chi-square test of score distributions. Mean (standard deviation) ratings were calculated. Responses to 29 questions (577 options) relating to appropriate patients and clinical scenarios for LAI use are reported. Results: Recommendations aligned with research on risk factors for nonadherence and poor outcomes for patients with schizophrenia/schizoaffective or bipolar disorder. Findings suggested, contrary to general practice patterns, that LAI use may be appropriate earlier in the disease course and in younger patients. Results for bipolar disorder were similar to those for schizophrenia but with less consensus. Numerous facilitators of LAI prescribing were considered important, particularly that LAIs may reduce relapses and improve outcomes. Conclusion: Findings support wider use of LAIs in patients with schizophrenia/schizoaffective and bipolar disorders beyond the setting of poor adherence and earlier use in the disease course. Keywords: expert consensus, schizophrenia, schizoaffective disorder, bipolar disorder, long-acting injectable antipsychotics
format article
author Sajatovic M
Ross R
Legacy SN
Correll CU
Kane JM
DiBiasi F
Fitzgerald H
Byerly M
author_facet Sajatovic M
Ross R
Legacy SN
Correll CU
Kane JM
DiBiasi F
Fitzgerald H
Byerly M
author_sort Sajatovic M
title Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1
title_short Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1
title_full Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1
title_fullStr Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1
title_full_unstemmed Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1
title_sort identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1
publisher Dove Medical Press
publishDate 2018
url https://doaj.org/article/71a5f44f201f4553ac0ebe5e8a53449b
work_keys_str_mv AT sajatovicm identifyingpatientsandclinicalscenariosforuseoflongactinginjectableantipsychoticsndashexpertconsensussurveypart1
AT rossr identifyingpatientsandclinicalscenariosforuseoflongactinginjectableantipsychoticsndashexpertconsensussurveypart1
AT legacysn identifyingpatientsandclinicalscenariosforuseoflongactinginjectableantipsychoticsndashexpertconsensussurveypart1
AT correllcu identifyingpatientsandclinicalscenariosforuseoflongactinginjectableantipsychoticsndashexpertconsensussurveypart1
AT kanejm identifyingpatientsandclinicalscenariosforuseoflongactinginjectableantipsychoticsndashexpertconsensussurveypart1
AT dibiasif identifyingpatientsandclinicalscenariosforuseoflongactinginjectableantipsychoticsndashexpertconsensussurveypart1
AT fitzgeraldh identifyingpatientsandclinicalscenariosforuseoflongactinginjectableantipsychoticsndashexpertconsensussurveypart1
AT byerlym identifyingpatientsandclinicalscenariosforuseoflongactinginjectableantipsychoticsndashexpertconsensussurveypart1
_version_ 1718398607156051968

Ejemplares similares